The biotech announced this morning that its dose-ascending Phase I/II study of its lead gene therapy for Duchenne muscular dystrophy flopped, sending the company into overdrive to hustle a higher dose into the clinic.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,